

claims and/or improper dependencies) and then reordered and renumbered, at the Examiner's request to facilitate completion of the reopened examination. The amendments proposed herein are intended to place the case in suitable condition for allowance.

Basis in the Specification for Claim 178(f) can be found in Example 2. More specifically, Example 2 describes the cloning of a human polynucleotide encoding a fragment of human GDNF using a PCR product generated by the amplification of a rat cDNA library. The PCR probe was amplified using primers designed to amplify the DNA fragment encoding amino acid 2 to 86 of SEQ ID NO:4. This PCR product was then successfully used as a probe to screen for polynucleotides encoding human GDNF. Therefore, Example 2 from pg. 57, line 24 through pg. 66, line 34 provides basis for Claim 178(f).

Applicants respectfully request consideration of the new claims presented herein. Applicants assert that no new matter has been added to the application as a result of the amendments presented herein. Applicants' representative would appreciate the opportunity to talk with the Examiner, in person or by telephone, to discuss any remaining issues.

If an extension of time is required, please consider this a request therefore.

Applicants believe no additional fees are due, however, the Commissioner is hereby authorized to charge any fees which may be required or credit any overpayment to Deposit Account No. 01-0519.

Robert L. Sharp



Attorney for Applicants  
Registration No: 45,609  
Phone: (805) 447-5992  
Date: October 17, 2002

Please send all future correspondence to:  
U.S. Patent Operations/RLS  
Dept. 4300 M/S 27-4-A  
AMGEN INC.  
One Amgen Center Drive  
Thousand Oaks, California 91320-1799